New drug combo shows promise for tough prostate cancer
NCT ID NCT05005728
First seen May 07, 2026 · Last updated May 07, 2026
Summary
This study tested a new drug called vudalimab, alone or with standard treatments, in 72 men with advanced prostate cancer that no longer responds to hormone therapy. The goal was to see if the drug is safe and can shrink tumors or lower PSA levels. Participants had to have cancer that was getting worse despite prior treatments.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC CASTRATION-RESISTANT PROSTATE CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Alaska Oncology and Hematology
Anchorage, Alaska, 99508, United States
-
Carolina Urologic Research Center
Myrtle Beach, South Carolina, 29572, United States
-
City of Hope
Duarte, California, 91010, United States
-
Columbia University
New York, New York, 10032, United States
-
Comprehensive Cancer Centers of Nevada
Las Vegas, Nevada, 89148, United States
-
GU Research Network/Urology Cancer Center
Omaha, Nebraska, 68130, United States
-
Mayo Clinic
Jacksonville, Florida, 32224, United States
-
Mayo Clinic
Rochester, Minnesota, 55905, United States
-
Mayo Clinic Hospital
Phoenix, Arizona, 85054, United States
-
Montefiore Medical Center
The Bronx, New York, 10461, United States
-
Northwest Cancer Specialists
Tigard, Oregon, 97223, United States
-
Palo Verde Hematology Oncology
Glendale, Arizona, 85304, United States
-
Rocky Mountain Cancer Centers
Lone Tree, Colorado, 80124, United States
-
SCRI Oncology Partners
Nashville, Tennessee, 37203, United States
-
Texas Oncology-Central South
Weslaco, Texas, 78596, United States
-
The University of Chicago Medical Center
Chicago, Illinois, 60637, United States
-
UPMC Hillman Cancer Center
Pittsburgh, Pennsylvania, 15232, United States
-
University of California, San Diego
San Diego, California, 92093, United States
-
University of Iowa Hospitals & Clinics
Iowa City, Iowa, 52242, United States
-
University of Kansas Clinical Research Center
Fairway, Kansas, 66205, United States
-
University of Pennsylvania
Philadelphia, Pennsylvania, 19104, United States
-
University of Washington/Seattle Cancer Care/Alliance
Seattle, Washington, 98109, United States
-
VA Greater Los Angeles
Los Angeles, California, 90064, United States
-
Virginia Cancer Specialists
Fairfax, Virginia, 22031, United States
-
Virginia Oncology Associates
Norfolk, Virginia, 23502, United States
-
XCancer New Mexico Oncology Hematology Consultants, Ltd.
Albuquerque, New Mexico, 87109, United States
Conditions
Explore the condition pages connected to this study.